A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The TIL trial is the world's first comparative phase 3 trial looking into the effect of T cell therapy in melanoma, and solid tumors in general.
from All Top News -- ScienceDaily https://ift.tt/GkR8iK6
from All Top News -- ScienceDaily https://ift.tt/GkR8iK6
Comments
Post a Comment